Replies to post #79971 on Innovation Pharmaceuticals Inc (IPIX)

[Jhawker]

When do you anticipate uplifting?

[WILD_4_IPIX]

Excellent SOX...Thanks Pal ! BTW, hope you don't mind that I share this on my FB page where I've gotten over 75 people to invest in CTIX over the last 2 years. Let me know and if I do not hear from you I will not post it. But since it's ALL TRUE, I will alter a bit and post it, hahaha. Thanks.

GO CTIX !

[Ultimate01]

Solid work as Always!

I just want to add "Advances in Inflammatory Bowel Disease" conferenece, December 4th.

http://orlando.eventful.com/events/advances-inflammatory-bowel-diseases-/E0-001-075840293-3

Go CTIX!!!

[F1ash]

Thanks Sox.

Proposed milestone addition

"Cellceutix has signed an agreement with a division of one of the largest U.S. pharmaceutical companies for testing Brilacidin as a component of certain implanted devices as a means to prevent infection. ... it is a logical application that could potentially add millions of dollars of revenue to the Company"


- See more at: http://cellceutix.com/cellceutix-december-to-be-momentous-month-in-companys-history/#sthash.dDmlF3Fi.dpuf

[Phoenix300]

Very nice

[TheHound]

Thanks Sox. A couple planned IND filings for 2015 if you want to add.

Also in our antibiotic/antifungal portfolio, we are actively testing several of our compounds both in house and through research grants at major universities. In the Gram-negative program, our lead compounds are active in laboratory testing against some of the most problematic pathogens, such as Pseudomonas, Klebsiella, E. coli and Acinetobacter. We have compounds active against drug-susceptible strains as well as multi-drug resistant strains that produce the Klebsiella pneumoniae carbapenamase (KPC) that confer resistance against other widely used antibiotics. Importantly, neither of these drug-resistance enzymes is active against our defensin mimetics. We expect to advance a Gram-negative drug into toxicology studies and file an IND for clinical development in 2015.

In our anti-fungal program, we have identified a series of defensin mimics that are highly active against Candida species and exhibit very low cytotoxicity against mammalian cell types. In June, we announced our collaboration with Fox Chase Chemical Diversity Center, which led to the award of a $1.5 million Phase 2B Small Business Innovation Research Grant. Laboratory experiments have shown that, like the antibacterial defensin-mimetics, the potential for resistance development by Candida is very low. Early studies of CTIX-1502 have delivered promising results in mouse models of Candida in both topical and systemic applications. Additional studies of our defensin mimetic compounds suggest possible new treatments for other fungal pathogens, including Aspergillus strains. We project to advance our lead antifungal drug with an IND filing in late 2015.

- See more at: http://cellceutix.com/cellceutix-provides-update-to-shareholders/#sthash.7hWfqyYJ.dpuf

[DaubersUP]

#1 and #3 to happen this week.

1). Cohort 9 completion IRB decision - First week of December.
2). Cohort 10 to begin thereafter in December
3). Ctix will meet with UofB in December to discuss the commencement of that phase 1/2 trial for K
4). Cellceutix management will be meeting with key opinion leaders at the 2014 Advances in Inflammatory Bowel Diseases, Crohn's & Colitis Foundation's Clinical & Research Conference on December 4-6, 2014 in Orlando, Florida.
5). The Phase 2 clinical trial of Brilacidin-OM for oral mucositis, an often debilitating effect of certain cancer therapies, is on target to commence in the second week of December
6.) Cellceutix will be meeting with the FDA in December to discuss advancing the clinical development of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Prurisol for treatment of psoriasis.

[Looping]

Great summary Sox...Thanks!

[choctaw]

Sox, thanks for the info. glta

[John B]

Nice list! Thanks Sox!

[alexwv]

December and 2015 will be unbelievable for CTIX!
Who are the suitors?
Thanks Sox!
"December Catalysts

- Start of cohort 10 (possible dosage increase)
- Start of B-OM (phase 2)
- Start of K + Cytarabine (phase 1b/2)
- FDA meetings on B-ABSSSI & P
- Release of B-ABSSSI bottom line data

2015 Q1 Catalysts

- Biotech Showcase (Jan. 12-14)
- Start of B-ABSSSI (phase 3)
- Start of P (phase 2/3)
- Completion of K (phase 1)
- Formulations of B-Ocular, B-Otic, diabetic foot infections

Milestones

- Completion of cohort 9 (350 mg/m2)
- B-ABSSSI phase 2b positive top-line data
- P phase 1 primary endpoint met
- Formulation of B stable at room "